News & Articles

Access SARS-CoV-2 IgG assay shows excellent agreement with the Genscript Surrogate Virus Neutralization Test

Rentschler Biopharma to provide cGMP manufacturing services for mRNA-based vaccine candidate, developed by BioNTech and Pfizer against SARS-CoV-2

Fluidigm COVID-19 campus safeguard program improves availability of non-invasive, saliva-based SARS-CoV-2 tests for higher education institutions

Early surgical treatment of leg ulcers caused by varicose veins improves healing and reduces the risk of the condition coming back

Promega and Incyte intend to work together in the future to develop the Promega OncoMate MSI Assay as a companion diagnostic

cPass is first commercially available product to rapidly detect neutralizing antibodies capable of eliminating virus

AstraZeneca anticipates entering clinical development in 2021

The technology is said to be superior at identifying cell types in human blood, providing faster and more reliable assessments for clinical decision making

The new Elecsys Anti-SARS-CoV-2 S test can quantitatively measure the level of antibodies against SARS-CoV-2 in patients who have been exposed to the virus

The collaboration aims to define threshold for neutralizing antibody sufficient to confer immunity

New indication allows this first FDA-approved biomarker-based test to be used as triage for positive cobas HPV tests run on cobas 6800/8800 Systems in primary screening or co-testing programs

The agreement is part of preparations for GMP production of material for the first clinical study of CG01

New test expands Roche molecular test menu for transplant patients, enabling simultaneous testing of BK virus with Cytomegalovirus and Epstein-Barr virus

Sanofi and GSK are scaling up the manufacturing of the antigen and adjuvant with the target of producing up to one billion doses in 2021

Data shows 100% concordance with results from Dartmouth-Hitchcock’s lab-based polymerase chain reaction (PCR) test method

The new AI technology will learn from past CT scans of COVID-19 pneumonia patients, reducing the burden on doctors making diagnoses

Antigen test reliably and quickly triages people suspected of SARS-CoV-2, with results ready in 15 minutes, allowing informed treatment decisions

Avacta and Liverpool School of Tropical Medicine collaborate to clinically validate saliva-based rapid coronavirus test being developed with Cytiva

Test delivers results in just 15 minutes with no instrumentation, using proven lateral flow technology with demonstrated sensitivity of 97.1% and specificity of 98.5%

First participants dosed in trial of AZD7442 to assess safety, tolerability and pharmacokinetics of the combination

QIAseq SARS-CoV-2 Primer Panel converts viral RNA samples into libraries ready for sequencing, whereas QIAGEN Digital Insights solutions support COVID-19 drug, vaccine and epidemiology research

Syndromic testing will streamline respiratory infection diagnosis as COVID-19 pandemic collides with start of flu season